Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer

B J Slotman, K H Njo, A de Jonge, O W Meijer, A B Karim

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Hypofractionation is the current choice for radiation therapy for patients with unresectable non-small cell lung cancer (NSCLC) at the authors' institute.

METHODS: In this nonrandomized study, three hypofractionated radiation schedules (40-Gy split course; 30-32 Gy in 6 fractions and 24 Gy in 3 fractions) are evaluated in 301 patients with unresectable Stage III NSCLC:

RESULTS: Patients with Stage IIIA disease treated with a 40-Gy split course had longer survival (P < 0.005) and a lower local relapse rate (P < 0.01), but a higher distant failure rate (P < 0.01) than those receiving 24-32 Gy. Survival for patients with Stage IIIA disease treated with 40 Gy at 1, 2, and 5 years was 47%, 22%, and 7%, respectively. For patients with Stage IIIB disease, the radiation scheme used did not correlate with survival and relapse rates. Survival at 1, 2, and 5 years was 30%, 9%, and 2%, respectively. The hypofractionated radiation schemes were well tolerated, and no severe complications were recorded.

CONCLUSIONS: In patients with Stage IIIA disease, 40-Gy split-course radiation therapy yields survival rates comparable to those achieved with conventional radiation therapy. In patients with Stages IIIB and IV NSCLC, 24 Gy in 3 weekly fractions yields survival rates comparable to those achieved with higher total doses given in more fractions.

Original languageEnglish
Pages (from-to)1885-93
Number of pages9
JournalCancer
Volume72
Issue number6
Publication statusPublished - 15 Sep 1993

Cite this

@article{c7002d9051814dd2a8890e8b2e189b7c,
title = "Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer",
abstract = "BACKGROUND: Hypofractionation is the current choice for radiation therapy for patients with unresectable non-small cell lung cancer (NSCLC) at the authors' institute.METHODS: In this nonrandomized study, three hypofractionated radiation schedules (40-Gy split course; 30-32 Gy in 6 fractions and 24 Gy in 3 fractions) are evaluated in 301 patients with unresectable Stage III NSCLC:RESULTS: Patients with Stage IIIA disease treated with a 40-Gy split course had longer survival (P < 0.005) and a lower local relapse rate (P < 0.01), but a higher distant failure rate (P < 0.01) than those receiving 24-32 Gy. Survival for patients with Stage IIIA disease treated with 40 Gy at 1, 2, and 5 years was 47{\%}, 22{\%}, and 7{\%}, respectively. For patients with Stage IIIB disease, the radiation scheme used did not correlate with survival and relapse rates. Survival at 1, 2, and 5 years was 30{\%}, 9{\%}, and 2{\%}, respectively. The hypofractionated radiation schemes were well tolerated, and no severe complications were recorded.CONCLUSIONS: In patients with Stage IIIA disease, 40-Gy split-course radiation therapy yields survival rates comparable to those achieved with conventional radiation therapy. In patients with Stages IIIB and IV NSCLC, 24 Gy in 3 weekly fractions yields survival rates comparable to those achieved with higher total doses given in more fractions.",
keywords = "Adenocarcinoma/mortality, Adult, Aged, Carcinoma, Non-Small-Cell Lung/mortality, Carcinoma, Squamous Cell/mortality, Female, Humans, Lung Neoplasms/mortality, Male, Middle Aged, Radiotherapy/adverse effects, Time Factors, Treatment Outcome",
author = "Slotman, {B J} and Njo, {K H} and {de Jonge}, A and Meijer, {O W} and Karim, {A B}",
year = "1993",
month = "9",
day = "15",
language = "English",
volume = "72",
pages = "1885--93",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. / Slotman, B J; Njo, K H; de Jonge, A; Meijer, O W; Karim, A B.

In: Cancer, Vol. 72, No. 6, 15.09.1993, p. 1885-93.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer

AU - Slotman, B J

AU - Njo, K H

AU - de Jonge, A

AU - Meijer, O W

AU - Karim, A B

PY - 1993/9/15

Y1 - 1993/9/15

N2 - BACKGROUND: Hypofractionation is the current choice for radiation therapy for patients with unresectable non-small cell lung cancer (NSCLC) at the authors' institute.METHODS: In this nonrandomized study, three hypofractionated radiation schedules (40-Gy split course; 30-32 Gy in 6 fractions and 24 Gy in 3 fractions) are evaluated in 301 patients with unresectable Stage III NSCLC:RESULTS: Patients with Stage IIIA disease treated with a 40-Gy split course had longer survival (P < 0.005) and a lower local relapse rate (P < 0.01), but a higher distant failure rate (P < 0.01) than those receiving 24-32 Gy. Survival for patients with Stage IIIA disease treated with 40 Gy at 1, 2, and 5 years was 47%, 22%, and 7%, respectively. For patients with Stage IIIB disease, the radiation scheme used did not correlate with survival and relapse rates. Survival at 1, 2, and 5 years was 30%, 9%, and 2%, respectively. The hypofractionated radiation schemes were well tolerated, and no severe complications were recorded.CONCLUSIONS: In patients with Stage IIIA disease, 40-Gy split-course radiation therapy yields survival rates comparable to those achieved with conventional radiation therapy. In patients with Stages IIIB and IV NSCLC, 24 Gy in 3 weekly fractions yields survival rates comparable to those achieved with higher total doses given in more fractions.

AB - BACKGROUND: Hypofractionation is the current choice for radiation therapy for patients with unresectable non-small cell lung cancer (NSCLC) at the authors' institute.METHODS: In this nonrandomized study, three hypofractionated radiation schedules (40-Gy split course; 30-32 Gy in 6 fractions and 24 Gy in 3 fractions) are evaluated in 301 patients with unresectable Stage III NSCLC:RESULTS: Patients with Stage IIIA disease treated with a 40-Gy split course had longer survival (P < 0.005) and a lower local relapse rate (P < 0.01), but a higher distant failure rate (P < 0.01) than those receiving 24-32 Gy. Survival for patients with Stage IIIA disease treated with 40 Gy at 1, 2, and 5 years was 47%, 22%, and 7%, respectively. For patients with Stage IIIB disease, the radiation scheme used did not correlate with survival and relapse rates. Survival at 1, 2, and 5 years was 30%, 9%, and 2%, respectively. The hypofractionated radiation schemes were well tolerated, and no severe complications were recorded.CONCLUSIONS: In patients with Stage IIIA disease, 40-Gy split-course radiation therapy yields survival rates comparable to those achieved with conventional radiation therapy. In patients with Stages IIIB and IV NSCLC, 24 Gy in 3 weekly fractions yields survival rates comparable to those achieved with higher total doses given in more fractions.

KW - Adenocarcinoma/mortality

KW - Adult

KW - Aged

KW - Carcinoma, Non-Small-Cell Lung/mortality

KW - Carcinoma, Squamous Cell/mortality

KW - Female

KW - Humans

KW - Lung Neoplasms/mortality

KW - Male

KW - Middle Aged

KW - Radiotherapy/adverse effects

KW - Time Factors

KW - Treatment Outcome

M3 - Article

VL - 72

SP - 1885

EP - 1893

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -